Humza Waheed
General Practice · Mexico, MONPI 1689938524
Payments from drug & device makers
Across 119 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$414
- Lilly USA, LLC$175
- Teva Pharmaceuticals USA, Inc.$114
- Lundbeck LLC$108
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$101
- Exact Sciences$94
- plus $893 from 24 others
What the payments were for
- Food & beverage$1,899100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $414 |
| Lilly USA, LLC | 13 | $175 |
| Teva Pharmaceuticals USA, Inc. | 7 | $114 |
| Lundbeck LLC | 6 | $108 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $101 |
| Exact Sciences | 5 | $94 |
| AstraZeneca | 6 | $93 |
| Neurocrine Biosciences, Inc. | 4 | $78 |
| Johnson & Johnson(2 entities) | 5 | $75 |
| Neurelis, Inc. | 4 | $65 |
| Dexcom, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Novo Nordisk | 3 | $43 |
| GSK | 3 | $38 |
| Alkermes, Inc. | 2 | $37 |
| Hologic Sales And Service, LLC | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Corcept Therapeutics | 2 | $30 |
| Indivior Inc. | 2 | $29 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Bayer | 2 | $26 |
| Boehringer Ingelheim | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $13 |
| Amgen | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$1,899 in reported general payments places this provider in the 90th percentile of 1,446 general practice providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XeljanzTofacitinib Citrate | 14 | $93,077 |
| JardianceEmpagliflozin | 123 | $90,561 |
| TrulicityDulaglutide | 46 | $55,208 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $54,509 |
| SpravatoEsketamine Hcl | 35 | $32,721 |
| EliquisApixaban | 33 | $26,172 |
| LinzessLinaclotide | 29 | $25,852 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 43 | $22,666 |
| OzempicSemaglutide | 20 | $21,731 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $21,390 |
| Humalog Kwikpen U-100Insulin Lispro | 60 | $12,791 |
| JanuviaSitagliptin Phosphate | 18 | $10,750 |
| MyrbetriqMirabegron | 15 | $10,478 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 51 | $10,150 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $10,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $25 | $113,227166 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $38 | $75,899115 claims |
| Lilly USA, LLCTrulicity, Humalog | $175 | $56,91358 claims |
| Johnson & JohnsonSpravato | $75 | $32,72135 claims |
| AbbVieLinzess | $414 | $25,85229 claims |
| Novo NordiskOzempic | $43 | $21,73120 claims |
| AstraZenecaSymbicort | $93 | $10,10239 claims |
| Indivior Inc.Suboxone | $29 | $8,40914 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $25 | $6,53611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,446 general practice providers in Missouri.
Other general practice in Mexico
- Bernard MillerSaint Louis$546K
- Baron GrutterGladstone$445K
- Shuka MoshiriSaint Louis$253K
- Arthur GreenbergKansas City$241K
- Robert CalaluceColumbia$189K
- David HoneycuttMonett$83K
- Suraiya SiddiqueMount Vernon$61K
- John FluckeLees Summit$60K
- Rex HudsonSaint Louis$49K
- David KaelinCape Girardeau$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.